Literature DB >> 11804981

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.

Mohamad Navab1, G M Anantharamaiah, Susan Hama, David W Garber, Manjula Chaddha, Greg Hough, Roger Lallone, Alan M Fogelman.   

Abstract

When apolipoprotein A-I mimetic peptides synthesized from either D- or L-amino acids were given orally to LDL receptor-null mice, only the peptide synthesized from D-amino acids was stable in the circulation and enhanced the ability of HDL to protect LDL against oxidation. The peptide synthesized from L-amino acids was rapidly degraded and excreted in the urine. When a peptide synthesized from D-amino acids (D-4F) was administered orally to LDL receptor-null mice on a Western diet, lesions decreased by 79%. When added to the drinking water of apoE-null mice, D-4F decreased lesions by approximately 75% at the lowest dose tested (0.05 mg/mL). The marked reduction in lesions occurred independent of changes in total plasma or HDL-cholesterol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804981     DOI: 10.1161/hc0302.103711

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  143 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Therapeutic reduction of coronary atheromatous plaque burden using bioengineered apoA-I Milano.

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

3.  Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.

Authors:  Shaila P Handattu; Geeta Datta; Richard M Epand; Raquel F Epand; Mayakonda N Palgunachari; Vinod K Mishra; Candyce E Monroe; Tamara D Keenum; Manjula Chaddha; G M Anantharamaiah; David W Garber
Journal:  J Lipid Res       Date:  2010-09-14       Impact factor: 5.922

4.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 5.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

6.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

7.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

8.  L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.

Authors:  Satoshi Imaizumi; Victor Grijalva; Mohamad Navab; Brian J Van Lenten; Alan C Wagner; G M Anantharamiah; Alan M Fogelman; Srinivasa T Reddy
Journal:  Drug Metab Lett       Date:  2010-08

Review 9.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

Review 10.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.